claim: global partnership to make available 5 million affordable, quality covid-19 rapid tests for low- and middle-income countries
evidence_1: these agreements are critical to fulfil the key objective of the act- accelerator: to ensure all countries, regardless of income, have fair access to new tests and tools to fight covid-19.", "both companies' tests are faster and cheaper than laboratory-based tests, enabling countries to increase the pace of testing, tracing and treating people for covid-19 at the point of care particularly in areas with under-resourced health systems.", "these two arrangements will make available to lmics 120 million antigen rapid diagnostic tests (ag rdts) - priced at a maximum of us$5 per unit - over a period of six months."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )